PDCD1 and non-small cell lung carcinoma: In the KEYNOTE-001 and KEYNOTE-24 trials, which were the first trials to use first- and second-line therapies with PD-1 antibody, pembrolizumab, in advanced NSCLC patients, PD-L1 TPS ≥ 50% resulted in response rates of 52% and 45%, respectively [27–29].